Elaine Lam, MD
University of Colorado, June 2003
Dr. Lam joined the division of Medical Oncology as an
Assistant Professor of Medicine at UCD on October 1, 2010. She previously
worked as a clinical pharmacist prior to attending medical school and
completing her residency at the University of Colorado, followed by fellowship
training at The Ohio State University. Outside of medicine, she enjoys spending
time with her husband and their two children.
Dr. Lam's clinical focus is in genitourinary malignancies
and her research interest is in the development of novel targeted agents. Dr. Lam is involved with clinical research
and patient care in the Urologic Oncology Program, as well as, the
Developmental Therapeutics Program.
Lam ET, O’Bryant CL, Basche M, Gustafson DL, Serkova N,
Baron A, Holden SN, Dancey J, Eckhardt G, and Gore L. A Phase I Study of Gefitinib, Capecitabine,
and Celecoxib In Patients With Advanced Solid Tumors. Mol Cancer Ther 2008;7(12):3685-94. PMID: 19074845.
Lam ET, Au JS, Otterson GA, Guillaume-Wientjes M, Chen L,
Shen T, Wei Y, Young D, Murgo AJ, Jenson RR, Grever M, and Villalona-Calero
MA. A Phase I Trial of Non-cytotoxic
Suramin as Modulator of Docetaxel and Gemcitabine Therapy in Previously Treated
Non-Small Cell Lung Cancer. Cancer
Chemother Pharmacol, Epub ahead of print 2010 Jan 28,
Lam ET, Ringel MD, Kloos RT, Prior T, Knopp MV, Vasko V,
Liang J, Sammet S, Hall NC, Wakely PE, Motoyasu S, Snyder P, Wei L, Arbogast D,
Collamore M, Wright JJ, Moley J, Villalona-Calero MA, and Shah MH. A Phase II Clinical Trial of the Multi-Kinase
Inhibitor, Sorafenib, in Metastatic Medullary Thyroid Cancer. J Clin Oncol, 2010;28(14):2323-30. Epub ahead
of print 2010 Apr 5, doi:10.1200/JCO.2009.25.0068. PMID: 20368568.
Lam ET, Goel S, Schaaf L, McCracken B, Desai K, Cropp GF,
Zhou Y, Johnson RG, Hannah AI, Mani S, and Villalona-Calero MA. Phase I Dose Escalation Trial of the Novel
Epothilone KOS-1584 in Patients with Advanced Solid Tumors (Submitted)